Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $686.8 million.

  • Neurocrine Biosciences' Receivables - Net rose 4335.21% to $686.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $686.8 million, marking a year-over-year increase of 4335.21%. This contributed to the annual value of $686.8 million for FY2025, which is 4335.21% up from last year.
  • Per Neurocrine Biosciences' latest filing, its Receivables - Net stood at $686.8 million for Q4 2025, which was up 4335.21% from $728.0 million recorded in Q3 2025.
  • Neurocrine Biosciences' Receivables - Net's 5-year high stood at $728.0 million during Q3 2025, with a 5-year trough of $147.8 million in Q1 2021.
  • Its 4-year average for Receivables - Net is $434.1 million, with a median of $450.7 million in 2024.
  • Per our database at Business Quant, Neurocrine Biosciences' Receivables - Net crashed by 53.84% in 2021 and then skyrocketed by 5131.99% in 2025.
  • Neurocrine Biosciences' Receivables - Net (Quarter) stood at $163.8 million in 2021, then soared by 168.19% to $439.3 million in 2023, then rose by 9.06% to $479.1 million in 2024, then soared by 43.35% to $686.8 million in 2025.
  • Its Receivables - Net stands at $686.8 million for Q4 2025, versus $728.0 million for Q3 2025 and $595.7 million for Q2 2025.